The Power of Partnership in Biotech

Zai Lab has been blazing a unique path to the future of biopharma since our founding in 2014, committed to driving the next wave of healthcare innovation. To help us achieve our mission, we have been focused on building important partnerships throughout the biotech and pharmaceutical communities across the globe.

Through our collaborations, we have built our reputation as a trusted partner for industry-leading global biopharmaceutical companies seeking access to the Chinese market and a long-term strategic collaborator for clinical development.

Our business development team has led the partnership effort with global organizations, pioneering collaboration models in greater China. We have worked seamlessly across all time zones, building a solid track record of execution with speed and quality in clinical development, regulatory review and commercialization.

One example of this success is within our oncology franchise focused on women’s cancer and lung and gastric cancers, which are leading causes of cancer death in the two largest markets globally – China and the US. Through partnerships, we have built a pipeline with 12 assets in late-stage development and an internally developed early-stage discovery pipeline.

At this week’s ASCO meeting, we will be presenting data from a new subgroup analysis of the Phase 3 PRIME study in patients in China with advanced ovarian cancer. The presentation (abstract #5551) will be Saturday, June 4, from 1:15 pm – 4:15 pm CDT during the Gynecologic Cancer session.

In addition, we are excited to be in good company with some of our partners, who are also presenting data at ASCO, including Amgen, Blueprint Medicines, Cullinan Oncology, Deciphera Pharmaceuticals, GSK, Macrogenics, Mirati and Novocure.

We look forward to seeing these presentations and posters and to our continued partnership.